| Literature DB >> 21731354 |
P K Bhoyar1, D O Morani, D M Biyani, M J Umekar, J G Mahure, Y M Amgaonkar.
Abstract
The objective of this study was to microencapsulate the anti-inflammatory drug (naproxen) to provide controlled release and minimizing or eliminating local side effect by avoiding the drug release in the upper gastrointestinal track. Naproxen was microencapsulated with lipid-like carnauba wax, hydrogenated castor oil using modified melt dispersion (modified congealable disperse phase encapsulation) technique. Effect of various formulation and process variables such as drug-lipid ratio, concentration of modifier, concentration of dispersant, stirring speed, stirring time, temperature of external phase, on evaluatory parameters such as size, entrapment efficiency, and in vitro release of naproxen were studied. The microspheres were characterized for particle size, scanning electron microscopy (SEM), FT-IR spectroscopy, drug entrapment efficiency, in vitro release studies, for in vitro release kinetics. The shape of microspheres was found to be spherical by SEM. The drug entrapment efficiency of various batches of microspheres was found to be ranging from 60 to 90 %w/w. In vitro drug release studies were carried out up to 24 h in pH 7.4 phosphate buffer showing 50-65% drug release. In vitro drug release from all the batches showed better fitting with the Korsmeyer-Peppas model, indicating the possible mechanism of drug release to be by diffusion and erosion of the lipid matrix.Entities:
Keywords: Carnauba wax; hydrogenated castor oil; lipid microspheres; modified melt dispersion technique; naproxen; release kinetics
Year: 2011 PMID: 21731354 PMCID: PMC3122038 DOI: 10.4103/0975-1483.80293
Source DB: PubMed Journal: J Young Pharm ISSN: 0975-1483
Effect of drug-lipid ratio on evaluatory parameters
| Batches with carnauba wax | A1 | A2 | A3 |
| Batches with hydrogenated castor oil | A4 | A5 | A6 |
| Drug:lipid | 1:3 | 1:4 | 1:5 |
| Modifier | No | No | No |
| Dispersant | PVA (0.5% w/v) | PVA (0.5% w/v) | PVA (0.5% w/v) |
| Stirring speed | 800 rpm | 800 rpm | 800 rpm |
| Stirring time | 3 min | 3 min | 3 min |
Effect of modifier concentration on evaluatory parameters
| Batch | B1 (25%w/w) | B2 (37.5%w/w) | B3 (50%w/w) |
|---|---|---|---|
| Mean diameter (μm) ± SD | 182 ± 33 | 235 ± 45 | 292 ± 34 |
| Entrapment efficiency (%) | 53.73% | 49.60% | 37.44% |
Figure 1Effect of drug-lipid (carnauba wax) ratio on in vitro dissolution profile of naproxen in pH 7.4 phosphate buffer
Figure 2Effect of drug-lipid (hydrogenated castor oil) ratio on in vitro dissolution profile of naproxen
Figure 3Effect of modifier (glycerol monosterate) concentration on in vitro dissolution profile of Naproxen
Figure 4Effect of dispersant concentration on in vitro dissolution profile of naproxen
Figure 5Effect of stirring speed on in vitro dissolution profile of Naproxen
Figure 6Effect of stirring time (emulsification) on in vitro dissolution profile of naproxen
Figure 7SEM photographs of microspheres (Batch A2) at ×100, ×110, ×190, ×500, ×1000, ×1500 and ×2000 magnification
Figure 8FT-IR Spectra of a) Naproxen b) Naproxen loaded microspheres c) Empty microspheres of carnauba wax d) Overlapping of and B
Correlation coefficient values for release kinetics of lipid microspheres
| Batch no. | Zero-order | First-order | Matrix (Higuchi) | Korsmeyer-Peppas | Hixson-Crowell |
|---|---|---|---|---|---|
| A1 | 0.5236 | 0.7938 | 0.9674 | 0.9746 | 0.7259 |
| A2 | 0.9140 | 0.9332 | 0.9252 | 0.9610 | 0.9508 |
| A3 | 0.9374 | 0.9247 | 0.9066 | 0.9610 | 0.9579 |
| B1 | 0.2223 | 0.7939 | 0.9585 | 0.9698 | 0.6885 |
| B2 | 0.2311 | 0.8148 | 0.9673 | 0.9786 | 0.7043 |
| B3 | 0.9259 | 0.9270 | 0.9289 | 0.9679 | 0.9631 |
| C1 | 0.9217 | 0.9428 | 0.9228 | 0.9545 | 0.9467 |
| C3 | 0.8317 | 0.9397 | 0.9622 | 0.9632 | 0.9145 |